David Parkinson, M.D.

Senior Venture Partner
New Enterprise Associates, Incorporated

David R. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to leading Nodality, Dr. Parkinson served in several leadership roles in the pharmaceutical industry, including; Senior Vice President, Oncology Research and Development, at Biogen Idec where he oversaw all oncology discovery research efforts and the development; Vice President, Oncology Development, at Amgen;  and Vice President, Global Clinical Oncology Development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix. Prior to joining industry, Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently serves as: a member of the National Cancer Policy Forum of the Institute of Medicine; co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium; Chairman of the AACR Finance Committee. Dr. Parkinson received his M.D. from the University of Toronto and completed a Hematology Fellowship at Royal Victoria Hospital at McGill University and was a Research Fellow at the New England Medical Center at Tufts University.  He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center.